Biomedicine / 报道
Ovarian vaccine trial tests feasibility
Nature Medicine published a phase 1 NeoVax ovarian cancer study on October 14. Its public abstract reports ten vaccinated patients: one newly diagnosed and nine at first recurrence. They had platinum-sensitive disease and received vaccination after standard platinum-based combination chemotherapy, with delayed anti-PD-1 treatment.
The personalized vaccine uses synthetic long peptides targeting each patient’s tumor neoantigens. Feasibility and safety were central: nine of twelve evaluable recurrent patients were vaccinated, compared with one of nine newly diagnosed patients. That difference matters for implementation. The abstract reports no unexpected safety signals or toxicity-related discontinuations; rare risks cannot be excluded.
Biomarkers suggested biological activity in six of ten, not six cures or established survival gains. Registry NCT04024878 describes an open, non-randomized phase 1 trial with 22 enrolled; enrollment and ten vaccinations are different counts. Small numbers, no randomized control and combined treatments prevent isolating vaccine efficacy. This report is limited to the public abstract and registry; the subscription full text was unavailable.
Sources and further reading
edited
Selected through a verified followed account: @EricTopol.